BATF was identified as a key transcription factor that mediates NK-cell dysfunction in AML, implying that the adoptive transfer of allogeneic healthy NK cells in combination with TGF-β inactivation or BATF suppression might be a promising method for AML immunotherapy (7). This evidence concerns the gene TGFB1 and acute myeloid leukemia.